Submission

Secondary myeloid neoplasms (sMN) are late events in non-transplanted acquired aplastic anemia (AA) or paroxysmal nocturnal hemoglobinuria (PNH) patients. This retrospective, multinational study (n=1008) reports how clinical, cytogenetic, and molecular characteristics influence the risk of sMN, suggesting rational diagnostic approaches. sMN presented high-risk morphological, cytogenetic, and...

Secondary myeloid neoplasms (sMN) are late events in non-transplanted acquired aplastic anemia (AA) or paroxysmal nocturnal hemoglobinuria (PNH) patients. This retrospective, multinational study (n=1008) reports how clinical, cytogenetic, and molecular characteristics influence the risk of sMN, suggesting rational diagnostic approaches. sMN presented high-risk morphological, cytogenetic, and...

Minimal residual disease (MRD) assessment retains high prognostic value in Acute Myeloid Leukemia patients (AML) undergoing intensive induction therapy. Secondary AML (s-AML) and therapy-related AML (t-AML) are usually under-represented in trial and are unlikely to respond to conventional induction and only few data are available...

Cytomegalovirus infection is one of the most common complications after allogeneic stem-cell transplantation (HSCT) still associated with significant morbidity and mortality. Although pre-emptive therapy (PET) is routinely used in the treatment of CMV after HSCT, its use is limited by unacceptable toxicities. Letermovir is the...

T-cell Large Granular Lymphocyte Leukemia (T-LGLL) is a chronic lymphoproliferative disorder characterized by the clonal expansion of T-LGL. Immunophenotype and mutational status discriminate symptomatic (i.e. CD8+ STAT3 mutated cases) from indolent patients [CD8+ STAT3 wild-type and CD4+ T-LGLL]. Several pro-inflammatory cytokines are known to play...